Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy by Hara, Fumikata et al.
 
Case Rep Oncol 2010;3:137–141 
DOI: 10.1159/000313921 
Published online: April 29, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
Fumikata Hara    Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center 
160 Kou 
Minamiumemoto-machi, Matsuyama 791-0280 (Japan) 
Tel. +81 89 999 1111, Fax +81 89 999 1100, E-Mail hfumikat @ shikoku-cc.go.jp 
 
137
   
Endometrial Metastasis from 
Breast Cancer during Adjuvant 
Endocrine Therapy 
Fumikata Haraa    Sachiko Kiyotoa    Daisuke Takabatakea    
Seiki Takashimaa    Kenjiro Aogia    Shozo Ohsumia    
Norihiro Teramoto
b    Rieko Nishimurab    
Shigemitsu Takashima
a  
Departments of aBreast Oncology, and bPathology, National Hospital Organization 
Shikoku Cancer Center, Matsuyama, Japan 
 
Key Words 
Breast cancer · Uterine metastases · Tamoxifen therapy 
Abstract 
It is well-known that tamoxifen increases the risk of endometrial cancer. Although 
metastasis to the uterus from breast cancer is uncommon, there have been some case 
reports on uterine metastasis. If an endometrial abnormality is detected, the differential 
diagnosis of whether the uterine tumor is metastatic or primary is very important to 
determine the course of treatment. We herein report a case in which we detected a 
uterine tumor during follow-up after treatment with tamoxifen, and demonstrate that 
GCDFP-15 is useful in diagnosing metastatic uterine tumors arising from breast cancer. 
Introduction 
Tamoxifen has played a critical role in the treatment of patients with hormone 
receptor-positive breast cancer [1]. However, it is well-known that tamoxifen increases 
the risk of endometrial cancer. This side effect occurs as a result of the agonistic effect of 
tamoxifen on the uterine endometrium. Therefore, gynecologic follow-up is necessary 
during tamoxifen treatment [2]. Although breast cancer metastasis to the uterus is 
uncommon, there have been a few case reports on uterine metastasis [3, 4]. If an 
endometrial abnormality is detected, differential diagnosis of whether the uterine tumor 
is metastatic or primary is very important to determine the type of treatment that should 
be administered. GCDFP-15 is a specific marker for breast cancer, which is very useful in 
defining whether the primary site was the breast [5]. We herein report a case where we 
detected a uterine tumor during follow-up after treatment with tamoxifen, and we further  
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confirm the usefulness of GCDFP-15 as a diagnostic marker for metastatic uterine tumors 
arising from breast cancer. 
Case Report 
A 44-year-old female presented with a mass, 5.5 × 4.5 cm in diameter, in her breast, and she was 
diagnosed with cT3aN1M0 stage IIIa invasive lobular breast carcinoma. Immunohistochemical staining 
for estrogen receptor was positive, but those for progesterone receptor and human epidermal growth 
factor receptor-2 were negative. The patients received neoadjuvant chemotherapy with 9 cycles of 
weekly docetaxel. She underwent a mastectomy and axillary lymph node dissection. Residual tumors 
remained in both the breast and lymph nodes. She received adjuvant chemotherapy with 4 cycles of 
adriamycin and cyclophosphamide, and tamoxifen was administered for two years, and then the patient 
was subsequently switched to anastrozole.  
Two months after treatment with anastrozole, the patient complained of abnormal uterine bleeding. 
Computed-tomography, magnetic resonance imaging (fig. 1) and transvaginal ultrasound revealed that 
her uterus had thickened endometrium, similar to the increased endometrial proliferation associated 
with tamoxifen administration. Endometrial curettage was performed. The pathological findings 
revealed signet ring cell adenocarcinoma, which is not typical of primary uterine tumors (fig. 2a). 
Immunohistochemical staining of the sample was positive for estrogen receptor, GCDFP-15 and CK7, 
and was negative for CK20 (fig. 2d, b and c, respectively). These findings were consistent with breast 
cancer that had metastasized to the uterus. Systemic examinations, including upper endoscopy, were 
performed, and there was no evidence suggesting other primary or metastatic diseases. Thereafter, the 
patient received systemic chemotherapy. However, she died as a result of pleural carcinomatosis and 
multiple bone metastasis 11 months after the diagnosis of recurrence. 
Discussion 
It is known that breast cancer can metastasize to many organ sites. The most 
frequently reported metastatic sites are bone, lung and liver, whereas the uterus is an 
uncommon organ for metastasis from breast cancer. Most of the uterine metastases are 
found on autopsy [6]. However, among the extragenital cancers, breast cancer is the most 
common cancer that metastasizes to the uterus, and invasive lobular carcinoma is 
particularly more likely to metastasize to the uterus [7].  
Tamoxifen has played an essential role in the treatment of hormone receptor-positive 
breast cancer. Based on the data generated during the EBCTCG’s meta-analysis, five years 
of treatment with tamoxifen can reduce the risk of both recurrence and mortality of 
breast cancer by approximately 30% [1]. This is caused by the antagonistic effect of 
tamoxifen on breast cancer cells. However, tamoxifen exerts a partial agonistic effect on 
the endometrium of the uterus. Therefore, treatment with tamoxifen increases the 
incidence of endometrial hyperplasias, polyps, and neoplasms. The relative risk of 
developing endometrial cancer following treatment with tamoxifen is approximately 2–4 
times higher than for patients who have not received the drug. These uterine tumors are 
frequently detected because patients experience unusual uterine bleeding [2]. However, 
the most common manifestation of uterine metastasis has also been reported to be uterine 
bleeding [8]. Therefore, it is very difficult to diagnose whether a uterine tumor is a 
primary tumor arising as a result of tamoxifen treatment, or whether it is a metastatic 
tumor. In the present case, tamoxifen was used as an adjuvant hormone therapy. Precise 
diagnosis affects critical decision-making with regard to the treatment of the uterine 
cancer (i.e. a primary uterine tumor should be resected, while a metastatic uterine tumor 
should be treated with systemic therapy as a first choice).   
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In the present case, histology revealed a signet ring morphology. A signet ring 
morphology is seen in gastrointestinal malignancies, but it can also be seen in breast 
cancer, in which it is regarded as a subtype of invasive lobular carcinoma with a poor 
prognosis [9]. According to recent reports, CK20 and CK7 are useful in diagnosing the 
origin of tumors with signet ring morphology. While gastric cancers are typically CK20 
positive and CK7 negative, breast cancers are generally CK20 negative and CK7 positive 
[10]. GCDFP is another marker known for having high sensitivity and specificity when 
used for the differential diagnosis of breast cancer [5]. In the present case, 
immunohistochemical staining of the uterine tumor revealed positivity for GCDFP and 
CK7, but negative staining for CK20. Therefore, the tumor was defined as being a 
metastatic tumor from invasive lobular carcinoma of the breast. 
Although there have so far only been a few reports on the prognosis of patients with 
metastatic uterine tumors from breast cancer, the patients in these reports (including the 
present report) all had a poor prognosis. However, given the limited number of reported 
cases, further studies are needed, along with a larger number of these cases, to further our 
understanding of the prognosis of these cancers and to determine the best course of 
treatment [11]. 
In conclusion, it should be kept in mind that breast cancer patients who have received 
tamoxifen may develop not only primary endometrial cancers, but may also sometimes 
demonstrate uterine metastases. 
 
 
 
 
 
Fig. 1. Abdominal magnetic resonance imaging revealed diffuse thickening of the uterus. 
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Fig. 2. Hematoxylin and eosin staining of endometrial specimen revealed a poorly differentiated 
adenocarcinoma with signet ring cell morphology (a). Immunohistochemistry showed strongly positive 
staining for CK7 (b), negative staining for CK20 (c) and positive staining for GCDFP-15 (d). 
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